Related references
Note: Only part of the references are listed.Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems
Ang Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Tumor Genetics Are Thrombogenic The Need for Action
Isabelle Mahe et al.
JACC: CARDIOONCOLOGY (2023)
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Dominique Farge et al.
LANCET ONCOLOGY (2022)
Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer
Miriam Kimpton et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2021)
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
Rick A. Vreman et al.
PHARMACOECONOMICS (2021)
Venous thromboembolism in cancer patients: a population-based cohort study
F. Mulder et al.
BLOOD (2021)
What is an efficient health intervention in Spain in 2020?
Jose Antonio Sacristan et al.
GACETA SANITARIA (2020)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States
Ang Li et al.
CANCER (2020)
SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)
A. J. Munoz Martin et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
Lucia Marin-Barrera et al.
CANCERS (2020)
New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting
Jiangyang Du et al.
CLINICAL DRUG INVESTIGATION (2020)
Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.
Emma Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic
Chris E. Holmes et al.
JCO ONCOLOGY PRACTICE (2020)
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery
Amanda Glickman et al.
GYNECOLOGIC ONCOLOGY (2020)
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
Giancarlo Agnelli
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life?
Andrew J. Lloyd et al.
VALUE IN HEALTH (2018)
Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England
C. Martinez et al.
PULMONARY CIRCULATION (2018)
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
Dolores Isla et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2017)
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
Charles Frost et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2014)
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
Freesia Horsted et al.
PLOS MEDICINE (2012)
Predicting Utility for Joint Health States: A General Framework and a New Nonparametric Estimator
Bo Hu et al.
MEDICAL DECISION MAKING (2010)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli et al.
LANCET ONCOLOGY (2009)
Assessing differences in utility scores: A comparison of four widely used preference-based instruments
Hwee-Lin Wee et al.
VALUE IN HEALTH (2007)
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism
V Pengo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Share Paper
